FIELD: biotechnology.
SUBSTANCE: method for removing an antibody with sulphated tyrosine from an aqueous mixture comprising an antibody in which tyrosine is sulphated and an antibody in which tyrosine is not sulphated, is proposed. These antibodies are antibodies against human LAG3. Tyrosine sulfation takes place in the CDR-L1 region. In addition, a composition for therapy, including antibodies against human LAG3, is proposed. The composition has less than 0.5% anti-hLAG3 antibodies that contain sulphated tyrosine on CDR-L1.
EFFECT: invention provides a method for purifying an antibody composition from contaminating antibody variants comprising sulphated tyrosine.
13 cl, 18 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF USE OF ANTIBODIES AGAINST HLA-G | 2019 |
|
RU2810326C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
